Mark Warren, MD, FACE is an endocrinologist and clinical associate professor at Campbell University School of Osteopathic Medicine.

Mark Warren, MD

Closing Thoughts on Hypoparathyroidism Management

In the final episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ the panelists share their key takeaways from the series discussion on hypoparathyroidism.

Led by the moderator, Dr. Kohlmeier, the panelists, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, emphasize that PTH-based therapy marks a shift toward physiologic therapy beyond calcium supplementation. They also stress that chronic hypoparathyroidism is a lifelong, multisystem disease requiring individualized care and ongoing research. The panel highlight the need for clear communication with providers, vigilant safety practices, and a medical advocate when possible. Lastly, they describe the era as exciting, noting that meaningful treatment options, such as palopegteriparatide and others in development, will enable truly personalized management plans. Their insights underscore the importance of integrating emerging therapies with comprehensive monitoring to optimize patient outcomes significantly.

Thank you for watching this HCPLive Peer Exchange series on hypoparathyroidism. Please subscribe to our newsletter for information on upcoming video series.

Videos

Emerging Therapies in Hypoparathyroidism

In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.

Led by the moderator, Dr. Kohlmeier, the expert endocrinologists, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examine the following critical questions:

What are your impressions of emerging therapies, such as eneboparatide (a PTH1R agonist), encaleret (a calcilytic agent), and MBX 2109 (PTH peptide prodrug) for their potential to manage chronic hypoparathyroidism?

The panel evaluates eneboparatide, a PTH1R agonist that closely mimics native parathyroid hormone signaling; MBX 2109, a PTH peptide prodrug engineered for sustained, physiologic PTH exposure; and encaleret, a calcilytic that modulates the calcium‑sensing receptor to enhance endogenous PTH release. Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ wraps up the series with the panelists’ final thoughts on the management of hypoparathyroidism.

In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.



Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism

In this episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism,’ the experts explore the importance of recommending medical advocates or medical alerts to patients as well as educational resources that are available for community providers to better manage hypoparathyroidism.

Led by the moderator, the panelists examine the following critical questions:

Do you recommend that your patients with chronic hypoparathyroidism have a medical advocate as well as a medical alert stating they are ‘Calcium Dependent’, and why is this important?

What other safety measures or educational tools do you recommend?

What educational resources and/or clinical tools would help community primary care providers and specialists better identify and manage chronic hypoparathyroidism?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Emerging Therapies in Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on several emerging therapies and their potential to manage chronic hypoparathyroidism.

In this episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism,’ the experts explore the importance of recommending medical advocates or medical alerts to patients as well as educational resources that are available for community providers to better manage hypoparathyroidism.



Multidisciplinary Approaches to Hypoparathyroidism Management

This episode, titled ‘Multidisciplinary Approaches to Hypoparathyroidism Management,’ features expert endocrinologists discussing the role of multidisciplinary collaboration among endocrinologists, nephrologists, and primary care providers.

Do you feel multidisciplinary input can improve outcomes in patients with hypoparathyroidism, and if so, how might we encourage collaboration among endocrinologists, nephrologists, and primary care providers?

How do you encourage adherence and engagement over time in your patients with hypoparathyroidism given they require chronic monitoring and often have several providers?

In the next episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism’, panelists will continue their discussion on hypoparathyroidism and highlight the importance of recommending medical advocates or medical alerts for patients as well as additional educational resources for clinicians to better identify and manage hypoparathyroidism.

This episode, titled ‘Multidisciplinary Approaches to Hypoparathyroidism Management,’ features expert endocrinologists discussing the role of multidisciplinary collaboration among endocrinologists, nephrologists, and primary care providers.



Mark Warren, MD

Articles